全文获取类型
收费全文 | 9421篇 |
免费 | 836篇 |
国内免费 | 15篇 |
专业分类
耳鼻咽喉 | 118篇 |
儿科学 | 416篇 |
妇产科学 | 364篇 |
基础医学 | 1357篇 |
口腔科学 | 121篇 |
临床医学 | 1144篇 |
内科学 | 1611篇 |
皮肤病学 | 147篇 |
神经病学 | 845篇 |
特种医学 | 317篇 |
外科学 | 1240篇 |
综合类 | 308篇 |
一般理论 | 8篇 |
预防医学 | 866篇 |
眼科学 | 146篇 |
药学 | 544篇 |
中国医学 | 9篇 |
肿瘤学 | 711篇 |
出版年
2023年 | 54篇 |
2022年 | 42篇 |
2021年 | 201篇 |
2020年 | 126篇 |
2019年 | 191篇 |
2018年 | 228篇 |
2017年 | 157篇 |
2016年 | 216篇 |
2015年 | 209篇 |
2014年 | 266篇 |
2013年 | 362篇 |
2012年 | 527篇 |
2011年 | 632篇 |
2010年 | 297篇 |
2009年 | 266篇 |
2008年 | 473篇 |
2007年 | 529篇 |
2006年 | 480篇 |
2005年 | 501篇 |
2004年 | 425篇 |
2003年 | 407篇 |
2002年 | 363篇 |
2001年 | 262篇 |
2000年 | 249篇 |
1999年 | 241篇 |
1998年 | 103篇 |
1997年 | 85篇 |
1996年 | 80篇 |
1995年 | 85篇 |
1994年 | 68篇 |
1993年 | 71篇 |
1992年 | 149篇 |
1991年 | 201篇 |
1990年 | 147篇 |
1989年 | 124篇 |
1988年 | 135篇 |
1987年 | 102篇 |
1986年 | 98篇 |
1985年 | 92篇 |
1984年 | 97篇 |
1983年 | 79篇 |
1982年 | 67篇 |
1981年 | 53篇 |
1980年 | 50篇 |
1979年 | 74篇 |
1978年 | 56篇 |
1974年 | 49篇 |
1973年 | 64篇 |
1972年 | 59篇 |
1967年 | 37篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
Fiene Marie Kuijper Uma V. Mahajan Seul Ku Daniel A.N. Barbosa Sheila M. Alessi Sherman C. Stein Kyle M. Kampman Brandon S. Bentzley Casey H. Halpern 《Neuromodulation》2022,25(2):253-262
ObjectivesCocaine is the second most frequently used illicit drug worldwide (after cannabis), and cocaine use disorder (CUD)-related deaths increased globally by 80% from 1990 to 2013. There is yet to be a regulatory-approved treatment. Emerging preclinical evidence indicates that deep brain stimulation (DBS) of the nucleus accumbens may be a therapeutic option. Prior to expanding the costly investigation of DBS for treatment of CUD, it is important to ensure societal cost-effectiveness.AimsWe conducted a threshold and cost-effectiveness analysis to determine the success rate at which DBS would be equivalent to contingency management (CM), recently identified as the most efficacious therapy for treatments of CUDs.Materials and MethodsQuality of life, efficacy, and safety parameters for CM were obtained from previous literature. Costs were calculated from a societal perspective. Our model predicted the utility benefit based on quality-adjusted life-years (QALYs) and incremental-cost-effectiveness ratio resulting from two treatments on a one-, two-, and five-year timeline.ResultsOn a one-year timeline, DBS would need to impart a success rate (ie, cocaine free) of 70% for it to yield the same utility benefit (0.492 QALYs per year) as CM. At no success rate would DBS be more cost-effective (incremental-cost-effectiveness ratio <$50,000) than CM during the first year. Nevertheless, as DBS costs are front loaded, DBS would need to achieve success rates of 74% and 51% for its cost-effectiveness to exceed that of CM over a two- and five-year period, respectively.ConclusionsWe find DBS would not be cost-effective in the short term (one year) but may be cost-effective in longer timelines. Since DBS holds promise to potentially be a cost-effective treatment for CUDs, future randomized controlled trials should be performed to assess its efficacy. 相似文献
6.
7.
8.
9.
A K Konstantinidis S J Barton I Sayers I A Yang J L Lordan S Rorke J B Clough S T Holgate J W Holloway 《The European respiratory journal》2007,30(1):40-47
Interleukin (IL)-13 plays a central role in asthma pathogenesis by binding to the IL-13 receptor, which is a heterodimer composed of the IL-13 receptor alpha1 subunit (IL-13Ralpha1) and IL-4Ralpha. The genetic diversity at the IL-13Ralpha1 gene (IL13RA1) locus on chromosome Xq24 was characterised and the association of identified polymorphisms with asthma and atopy phenotypes examined. The promoter and coding region of IL13RA1 were screened for common genetic variants, and polymorphisms found were genotyped in a large cohort of 341 asthmatic Caucasian families (each containing at least two asthmatic siblings) and 182 nonasthmatic control subjects. Genetic association was determined using case-control and transmission disequilibrium test analyses. Two common polymorphisms were identified, a newly found thymidine (T) to guanine (G) transition of nucleotide -281 (-281T>G) single nucleotide polymorphism in the IL13RA1 promoter and the previously described 1365A>G variant in the IL13RA1 proximal 3' untranslated region. No significant association of either -281T>G or 1365A>G with risk of asthma or atopy phenotypes was found, apart from a suggestive association between the IL13RA1 -281T/1365A haplotype and raised total serum immunoglobulin E levels in adult female asthmatics. These findings indicate that the interleukin-13 receptor alpha1 subunit gene -281T>G and 1365A>G polymorphisms do not contribute to asthma susceptibility or severity, although the interleukin-13 receptor alpha1 subunit gene locus might be involved in the control of immunoglobulin E production. 相似文献
10.